logo
Share SHARE
FONT-SIZE Plus   Neg

VIVUS Says FDA Extends Qnexa PDUFA Date

VIVUS Inc. (VVUS: Quote) said Monday that the U.S. Food and Drug Administration has extended the Prescription Drug User Fee Act date for its review of the Qnexa New Drug Application by three months from April 17 to July 17, 2012.

On April 4, following the FDA's request, VIVUS submitted the Qnexa Risk Evaluation and Mitigation Strategy, which was considered a major amendment to the NDA. The submission consisted of proposed REMS materials.

Since the receipt date was within three months of the user fee goal date, the FDA is extending the Prescription Drug User Fee Act date by three months to provide time for a full review of the submission, the company noted.

The Qnexa NDA seeks approval for the treatment of obesity, including weight loss and maintenance of weight loss for obese patients with weight-related co-morbidities such as hypertension, type 2 diabetes or dyslipidemia.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Mercedes-Benz Vans Friday said it would invest around $500 million to create a plant in Charleston, South Carolina to explore the future growth potential in North American Van market. After many years on the outside, tech giant Apple Inc. (AAPL) will finally be added to the Dow Jones Industrial Average, S&P Dow Jones Indices announced on Friday. Apple, the maker of the iPhone and iPad, will replace telecom giant AT&T Inc. (T) in the well-known stock market index. The Federal Reserve announced on Thursday that all of the thirty one largest banking institutions in the U.S. have passed the annual supervisory stress test, reflecting continued broad improvement in their capital positions since the financial crisis in 2008. These also included U.S. subsidiaries of large foreign banks.
comments powered by Disqus
Follow RTT